C4 Therapeutics/$CCCC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About C4 Therapeutics
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
- Ticker
- $CCCC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 104
- Headquarters
- Watertown, United States
- Website
- www.c4therapeutics.com
C4 Therapeutics Metrics
BasicAdvanced
$428m
-
-$0.91
2.95
-
Price and volume
Market cap
$428m
Beta
2.95
52-week high
$5.17
52-week low
$1.69
Average daily volume
3.1m
Financial strength
Total debt to equity
24.951
Profitability
EBITDA (TTM)
-99.336
Gross margin (TTM)
86.34%
Net profit margin (TTM)
-289.44%
Operating margin (TTM)
-288.34%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$340,000
Management effectiveness
Valuation
Price to revenue (TTM)
12.33
Price to book
1.72
Price to tangible book (TTM)
1.72
Growth
Revenue change (TTM)
2.33%
Earnings per share change (TTM)
-42.58%
3-year revenue growth (CAGR)
29.78%
3-year earnings per share growth (CAGR)
-31.72%
What the Analysts think about C4 Therapeutics
Analyst ratings (Buy, Hold, Sell) for C4 Therapeutics stock.
C4 Therapeutics Financial Performance
Revenues and expenses
C4 Therapeutics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.